Global Sleeve Gastrectomy Devices Market - 2021-2028
Sleeve gastrectomy is a surgical weight-loss procedure. By surgical removal a large portion of the stomach is reduced to about 15% of its original size along the greater curvature.
The sleeve gastrectomy devices market size was valued at US$ YY million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).
Increasing incidence of obesity is estimated to drive the sleeve gastrectomy devices market.
In 2020, 39% of adults in the world were overweight. Globally, one in five children and adolescents are overweight. Surgical weight-loss procedure, sleeve gastrectomy is also called a vertical sleeve gastrectomy. This procedure is performed laparoscopically, through multiple small incisions it involves inserting small instruments in the upper abdomen. During sleeve gastrectomy, around 80% of the stomach is removed, leaving a tube-shaped stomach about the size and shape.
Limitation of the size of the stomach restricts the amount of food one can consume, the procedure in addition prompts hormonal changes that assist with weight loss. These hormonal changes also help relieve conditions associated with being overweight, such as high blood pressure or heart disease. Sleeve gastrectomy is done to help lose excess weight and reduce risk of potentially life-threatening weight-related health problems. This gastrectomy is done to help lose excess weight and reduce your risk of potentially life-threatening weight-related health problems. Sleeve gastrectomy is typically done only after one has tried to lose weight by improving diet and exercise habits. It is possible to lose approximately 60% or even more of excess weight within two years. Sleeve gastrectomy in addition to weight loss, may improve or resolve conditions related to being overweight, including heart disease and high blood pressure.
The sleeve gastrectomy is a laparoscopic procedure. The procedure involves in the abdomen making five or six small incisions and performing it using a video camera (laparoscope) and long instruments placed through these small incisions. About 75% of the stomach is removed during the laparoscopic sleeve gastrectomy, leaving a narrow gastric"sleeve" or "tube". During the sleeve gastrectomy no intestines are removed or bypassed. The LSG takes one to two hours to complete. It is primarily used as part of a staged approach to surgical weight loss. Patients with a very high (BMI) or a longer procedure or at risk for undergoing anesthesia due to lung or heart problems may benefit from this approach. Sometimes before surgery the decision to proceed with a two-stage approach is made due to the known risk factors. In other patients during the operation the decision to perform sleeve gastrectomy (instead of gastric bypass) is made. Intraoperatively, reasons for making this decision include an extensive scar tissue or excessively large liver that makes the gastric bypass procedure too long or unsafe.
As a first stage procedure in patients who undergo LSG, the second stage is performed 12 to 18 months after weight loss has occurred significantly and the risk of anesthesia is much lower. Though this approach involves two procedures, it is believed that it is effective and safe for selected patients. LSG can also be used as a primary procedure. There is relatively less data regarding the use of laparoscopic sleeve gastrectomy as a stand-alone procedure in patients with lower BMI.
Bleeding, leakage and gastric fistulae are the most common intraoperative complications and postoperative complications after sleeve gastrectomy. The majority of problems are focused on the post-operative effects rather than intra-operative leaks and bleeds. The methods using for detecting intra-operative staple line bleeds are not standardized. Still, they present a different challenge in which bleeds are often undocumented or considered a nuisance and are routinely treated with cauterization, sutures, sealants, and clips or might be self-resolved by the application of pressure along the staple line. Very less studies have addressed the impact of intra-operative leaks and bleed on other complications or factors such as operative time, cost, and length of stay. A variety of complications can happen in the post-operative period. The most common complications among patients during this time include pulmonary emboli, hemorrhage, chest infections, abscess, incisional hernia, laparoscopy for retained drain, anatomic leakage, wound infections, gastroesophageal reflux disease (GERD), and rhabdomyolysis in men. Also, dumping usually occurs around an hour after eating and presents with bloating, flushing, diarrhea, and light-headedness symptoms.
LDL cholesterol and total cholesterol levels were more different in males. Over the last years, some investigations have proven that women are more addicted to sweets than meat products. During reproductive ages, women are naturally susceptible to iron deficiency and anemia. Men, on the other side, tend to be heavier with larger muscle mass that may increase surgical time and general postoperative complications, including rhabdomyolysis
COVID-19 has affected the healthcare industry. To stop its growth, government-imposed lockdown. People are fearful they will experience negative health and occupational effects from the COVID-19 pandemic. All the manufacturing, as well as supply chains, have been hit due to the COVID-19 restrictions. Hence, the sleeve gastrectomy devices market has seen a decrease in its market.
Novel technologies and techniques are being developed that can be used in the treatment of transmural defects. The various devices include: through-the-scope clips (TTSC), cap mounted clips, covered self-expandable metal stents (CSEMS), tissue sealants, endoscopic sutures, cardiac septal defect occluders, septotomies, balloon dilators, endoscopic internal drainage with double pigtails (EID) and endoscopic vacuum therapy (EVT). There is experience with endoscopic suturing use in the treatment of gastrointestinal closure/ leak fistula. These can be acute or chronic and often result in complications from surgical anastomoses and stapled tissue divisions such sleeve gastroplasty.
Suturing is often used in connection with other therapies including stents and glue. The StomaphyX suturing system was used to treat gastric leaks in two bariatric patients. The OverStitch device achieved closure in 3 of 7 patients with gastrogastric fistulae after gastric bypass. This device has been used for a variety of fistulae. Patients who are fortunate enough to have removal of their feeding tube after gastrostomy usually have wound closure, but occasionally there is a persistent gastrocutaneous fistula. A variety of closure techniques and endoscopic suturing may be employed as the sole intervention or in combination with other therapies.
Increased government and private funding, growing preference among physicians and patients to perform procedures in a hospital-based environment. In many developed and developing countries hospital facilities are well equipped with the latest innovative technologies. And the skilled staff in these procedures provide all the necessary facilities to carry out such treatments. For a district general hospital serving 250,000, the workload entails about 3500 procedures annually, performed during ten half-day routine sessions plus emergency work. High standards of training and experience are provided to the staff, who work to build accommodation designed to promote efficient and safe practice. A huge number of patients rely on hospitals because they engage closely with many reimbursement authorities, suppliers, and government organizations. The number of sleeve gastrectomy performed in hospitals and clinics is increasing, which will drive the sales of sleeve gastrectomy devices.
The availability of technologically advanced medical facilities in North America is driving the market growth is this region. The surge in the incidences of obesity is likely to increase the demand for bariatric surgery by boosting the market of laparoscopy. Increasing number of gastrectomy procedures in North America is also expected to drive the market growth. For instance, each year, nearly 200,000 Americans have bariatric surgery. Still more than an estimated 24 million are enough to qualify for the operation and many of them are struggling with the decision to have such a radical treatment, the only one that leads to intense and lasting weight loss for virtually everyone who has it.
Major key players in the sleeve gastrectomy devices market are Intutive Surgical Inc., Apollo Endosurgery Inc., TransEnterix Inc., Cousin Biotech, EnteroMedics Inc., Medtronics Plc., Agency for Medical Innovations, Aspire Bariatrics Inc., Mediflex Surgical Products. and Ethicon Inc.
The global sleeve gastrectomy devices market report would provide an access to an approx. 52 market data table, 40 figures and 180 pages.